AjaDuo Update Podcast- Diabetes News & Clinical Updates

About AjaDuo Update Podcast- Diabetes News & Clinical Updates

Want to stay updated with the latest in diabetes research, reviews, and perspectives? Our content is curated, written, and edited by practicing healthcare professionals with clinical and scientific expertise in diabetes care. Our editorial team is comprised of highly-trained physicians. Our summaries are designed to deliver concise, relevant insights to support effective diabetes management in clinical practice. New summaries are available monthly.

Publisher

ImagicaHealth

Category

health & fitness

Language

en

Explicit

No

First episode

26 Mar 2026

Latest episode

30 Sept 2026

Latest episodes

29 episodes in the feed.

1. 

   30 Sept 2026

   Type 2 diabetes mellitus: emerging mechanistic insights, evolving therapeutic strategies, and future perspectives

   Abstract Type 2 diabetes mellitus (T2DM) is a complex and progressive metabolic disorder driven by interactions among genetic susceptibility, environmental influences, and metabolic dysfunction. Although insulin resistance and pancreatic β-cell dysfunction remain central to disease pathogenesis, emerging evidence highlights the contributions of chronic low-grade inflammation, gut microbiota dysbiosis, mitochondrial dysfunction, and adipose tissue remodeling in disease progression. Recent advances have shifted the management paradigm beyond glycemic control towards comprehensive cardiometabolic risk reduction, with newer therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose co transporter-2 (SGLT2) inhibitors, and dual incretin receptor agonists demonstrating significant cardiovascular, renal, and metabolic benefits. Emerging concepts including prediabetes remission, early metabolic reversal, and precision medicine are further reshaping preventive and therapeutic strategies. However, important challenges remain regarding early risk identification, quitable access to advanced therapies, long-term treatment adherence, and implementation of evidence-based interventions in routine clinical practice. This review synthesizes contemporary mechanistic insights, evolving therapeutic approaches, and future directions in T2DM management, highlighting opportunities for personalized care and improved long term outcomes.

2. 

   30 Sept 2026

   Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study

   OBJECTIVE We aimed to explore the heterogeneity of empagliflozin treatment effects on major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and all-cause mortality (ACM) across sociodemographic and cardiovascular disease (CVD) subgroups of adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Using 2014–2020 Medicare claims data, we examined rates of MACE (e.g., composite myocardial infarction, stroke, all-cause mortality [ACM]), HHF, and ACM among propensity score–matched individuals aged ≥65 years with T2D initiating empagliflozin compared with those prescribed dipeptidyl peptidase-4 inhibitors (DPP4is) and those prescribed GLP-1 receptor agonists (GLP-1RAs). We calculated hazard ratios(HRs) and incidence rate differences (IRDs) overall and by age, sex, race or ethnicity, socioeconomic factors, and baseline CVD. RESULTS Empagliflozin was associated with decreased risk of MACE (HR 0.77, 99.9% CI [0.69, 0.85]; IRD = −10.3 [−14.1, −6.4]); HHF (HR 0.72 [0.67, 0.79]; IRD = −18.3 [−22.9, −13.6]); and ACM (HR0.66 [0.57, 0.76]; IRD = −8.6 [−11.4, −5.8]) compared with DPP4is. Effect heterogeneity by baseline CVD was present across all outcomes on the IRD scale but only for HHF on the HR scale. Empagliflozin was also associated with decreased risk of HHF (HR 0.88 [0.81, 0.95]; IRD = −6.9 [−10.8, −3.1]) versus GLP-1RAs, with effect heterogeneity by baseline CVD on the IRD scale. No effect heterogeneity was observed by sociodemographic factors, although a numeric trend suggested greater absolute benefit in patients aged ≥75 years compared with those aged 65–74 years. CONCLUSIONS Empagliflozin reduced cardiovascular events across sociodemographic and CVD subgroups compared withboth DPP4is and GLP-1RAs, with higher absolute benefits observed in those with prevalent CVD.

3. 

   30 Sept 2026

   Empagliflozin improves serum uric acid and early cardiometabolic outcomes in asymptomatic hyperuricemia among patients with type 2 diabetes- A 6-month observational study

   Abstract Asymptomatic hyperuricemia is common among patients with type 2 diabetes and has been associated with increased cardiovascular risk. However, evidence regarding the effects of empagliflozin on serum uric acid (SUA) and cardiovascular outcomes in this population remains limited. This study aimed to evaluate the impact of empagliflozin on serum uric acid (SUA) levels and early cardiometabolic outcomes in patients with type 2 diabetes and asymptomatic hyperuricemia. This 6-month observational study was conducted at a tertiary hospital in Vietnam. A total of 247 patients with type 2 diabetes were included in the cross-sectional analysis. Among them, 63 patients with asymptomatic hyperuricemia who did not meet indications for urate-lowering therapy were followed prospectively for 6 months and received either empagliflozin (10–25 mg/d) or background therapy without empagliflozin. Changes in serum uric acid SUA, HbA1c, fasting plasma glucose, and major adverse cardiovascular events (MACE) were assessed. Among the 247 participants, 73 (29.6%) had asymptomatic hyperuricemia and showed a significantly higher incidence of MACE than those without hyperuricemia (34.2% vs 8.6%; adjusted odds ratio 5.77, 95% CI: 2.49–13.39). Serum uric acid (SUA) demonstrated good predictive performance for MACE (AUC 0.741), cardiovascular mortality (AUC 0.804), and myocardial infarction (AUC 0.745). After 6 months, serum uric acid (SUA) decreased more significantly in the empagliflozin group than in the control group (−101.66 ± 76.44 vs −45.90 ± 86.36 µmol/L; P = .009). Fasting plasma glucose also improved significantly, whereas the reduction in HbA1c was not statistically significant. In patients with type 2 diabetes and asymptomatic hyperuricemia, elevated serum uric acid (SUA) was associated with increased cardiovascular risk. Empagliflozin significantly reduced serum uric acid (SUA) and improved fasting plasma glucose, with a potential trend toward favorable cardiovascular outcomes.

Contact AjaDuo Update Podcast- Diabetes News & Clinical Updates

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.